Regulatory Issues of Platform Trials: Learnings from EU-PEARL.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
received:
19
10
2023
accepted:
27
02
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
aheadofprint
Résumé
Although platform trials have many benefits, the complexity of these designs may result not only in increased methodological but also regulatory and ethical challenges. These aspects were addressed as part of the IMI project EU Patient-Centric Clinical Trial Platforms (EU-PEARL). We reviewed the available guidelines on platform trials in the European Union and the United States. This is supported and complemented by feedback received from regulatory interactions with the European Medicines Agency and the US Food and Drug Administration. Throughout the project we collected the needs of all relevant stakeholders including ethics committees, regulators, and health technology assessment bodies through active dialog and dedicated stakeholder workshops. Furthermore, we focused on methodological aspects and where applicable identified the corresponding guidance. Learnings from the guideline review, regulatory interactions, and workshops are provided. Based on these, a master protocol template was developed. Issues that still need harmonization or clarification in guidelines or where further methodological research is needed are also presented. These include questions around clinical trial submissions in Europe, the need for multiplicity control across the whole master protocol, the use of non-concurrent controls, and the impact of different randomization schemes. Master protocols are an efficient and patient-centered clinical trial design that can expedite drug development. However, they can also introduce additional operational and regulatory complexities. It is important to understand the different requirements of stakeholders upfront and address them in the trial. While relevant guidance is increasing, early dialog with relevant stakeholders can help to further support such designs.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Innovative Medicines Initiative
ID : 853966
Organisme : EFPIA
Informations de copyright
© 2024 The Authors, Johnson & Johnson Innovative Medicines and Sanofi. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
EU‐PEARL. EU‐PEARL: about EU‐PEARL. <https://eu‐pearl.eu/project/#what>. (18 August 2023).
Koenig, F. et al. Current state‐of‐the‐art and gaps in platform trials: 10 things you should know, insights from EU‐PEARL. eClinicalMedicine 67, https://doi.org/10.1016/j.eclinm.2023.102384 (2024).
EU‐PEARL. EU‐PEARL: D2.1 report on terminology and scenarios for platform trials and master protocols. <https://eu‐pearl.eu/wp‐content/uploads/2020/06/EU‐PEARL_D2.1_Report‐on‐Terminology‐and‐Scenarios‐for‐Platform‐Trials‐and‐Masterprotocols.pdf>. (17 August 2023).
US Food and Drug Administration. Interacting with the FDA on complex innovative trial designs for drugs and biological products: guidance for industry. <https://www.fda.gov/media/130897/download> (17 January 2020).
US Food and Drug Administration. Critical path innovation meetings (CPIM). <https://www.fda.gov/drugs/new‐drugs‐fda‐cders‐new‐molecular‐entities‐and‐new‐therapeutic‐biological‐products/critical‐path‐innovation‐meetings‐cpim>. (24 February 2023).
European Commission. Communication from the Commission — Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT‐1). (2010/C 82/01). <https://eur‐lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2010:082:0001:0019:EN:PDF> (25 January 2023).
Heads of Medicines Agencies. Clinical Trials Coordination Group (CTCG). <https://www.hma.eu/about‐hma/working‐groups/clinical‐trials‐coordination‐group.html> (9 January 2024).
Heads of Medicines Agencies. Clinical Trials Facilitation and Coordination Group (CTFG). <https://www.hma.eu/about‐hma/working‐groups/clinical‐trials‐facilitation‐and‐coordination‐group.html> (9 January 2024).
European Medicines Agency. Clinical Trials information system ‐ European Medicines Agency. <https://www.ema.europa.eu/en/human‐regulatory/research‐development/clinical‐trials/clinical‐trials‐information‐system> (6 January 2023).
US Food and Drug Administration. Electronic common technical document. <https://www.fda.gov/drugs/electronic‐regulatory‐submission‐and‐review/electronic‐common‐technical‐document‐ectd> (9 January 2024).
European Medicines Agency. EMA ‐ about us. <https://www.ema.europa.eu/en/documents/other/about‐us‐european‐medicines‐agency‐ema_en.pdf> (9 January 2024).
US Food and Drug Administration. what we do. <https://www.fda.gov/about‐fda/what‐we‐do> (9 January 2024).
US Food and Drug Administration. Investigational New Drug (IND) Application. <https://www.fda.gov/drugs/types‐applications/investigational‐new‐drug‐ind‐application> (9 January 2024).
European Medicines Agency. Innovation in medicines. <https://www.ema.europa.eu/en/human‐regulatory/research‐development/innovation‐medicines> (24 February 2023).
Clinical Trials Facilitation and Coordination Group (CTFG). Recommendation paper on the initiation and conduct of complex clinical trials. <https://www.hma.eu/fileadmin/dateien/Human_Medicines/01‐About_HMA/Working_Groups/CTFG/2019_02_CTFG_Recommendation_paper_on_Complex_Clinical_Trials.pdf> (17 January 2023).
European medicines agency. Complex clinical trials ‐ questions and answers. EMA/298712/2022. <https://health.ec.europa.eu/system/files/2022‐06/medicinal_qa_complex_clinical‐trials_en.pdf> (17 January 2023).
US Food and Drug Administration. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics: guidance for industry. <https://www.fda.gov/media/120721/download> (17 January 2023).
US Food and Drug Administration. Master protocols for drug and biological product development ‐ guidance for industry. <https://www.fda.gov/media/174976/download> (9 January 2024).
US Food and Drug Administration. COVID‐19: master protocols evaluating drugs and biological products for treatment or prevention: guidance for industry. <https://www.fda.gov/media/148739/download> (17 January 2023).
European Medicines Agency. Concept paper on platform trials. EMA/CHMP/840036/2022. <https://www.ema.europa.eu/en/documents/scientific‐guideline/concept‐paper‐platform‐trials_en.pdf> (17 January 2023).
Gidh‐Jain, M., Parke, T., König, F., Spiertz, C. & Mesenbrink, P. Developing Generic Templates to Shape the Future for Conducting Integrated Research Platform Trials. Submitted. Trials (2023).
EFPIA. Accelerating adoption of complex clinical trials in europe and beyond: a multi‐stakeholder workshop. <https://www.efpia.eu/media/636599/workshop‐report‐_accelerating‐ccts_final.pdf> (6 January 2023).
EU‐PEARL. EU‐PEARL 2nd stakeholder workshop. <https://eu‐pearl.eu/workshops/eu‐pearl‐2nd‐stakeholder‐workshop‐2/> (24 February 2023).
EFPIA. Accelerating Adoption of Complex Clinical Trials in Europe and beyond. A multi‐stakeholder workshp to develop shared solutions for the use of complex clinical trials to optimise drug development in Europe. <https://www.efpia.eu/news‐events/events/efpia‐event/accelerating‐adoption‐of‐complex‐clinical‐trials‐in‐europe‐and‐beyond> (01 Feburary 2023).
Official Journal of the European Union. Communication from the commission — Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT‐1). 2010/C 82/01. <https://eur‐lex.europa.eu/legal‐content/EN/TXT/?uri=CELEX%3A52010XC0330%2801%29> (2010).
European Commission. Questions and answers document – Regulation (EU) 536/2014 – Version 6.5. <https://health.ec.europa.eu/document/download/bd165522‐8acf‐433a‐9ab1‐d7dceae58112_en?filename=regulation5362014_qa_en.pdf> (25 August 2023).
Sharma, V. Not a smooth ride: how one of the first studies navigated the EU. Clinical Trial Portal. <https://pink.pharmaintelligence.informa.com/PS146805/Not‐A‐Smooth‐Ride‐How‐One‐Of‐The‐First‐Studies‐Navigated‐The‐EU‐Clinical‐Trial‐Portal?utm_medium=email&utm_source=sfmc&utm_campaign=Pink+Sheet+My+View+Email&utm_id=4394294&sfmc_id=153527612> (28 November 2022).
European Medicines Agency. Scientific advice and protocol assistance. <https://www.ema.europa.eu/en/human‐regulatory‐overview/research‐and‐development/scientific‐advice‐and‐protocol‐assistance#ema‐inpage‐item‐11152> (8 January 2024).
Paul‐Ehrlich‐Insitut (PEI). Advice concept. <https://www.pei.de/EN/regulation/advice/advice‐concept/advice‐concept‐node.html> (8 January 2024).
US Food and Drug Administration. Formal meetings between the FDA and sponsors or applicants. <https://www.fda.gov/media/72253/download> (8 January 2024).
US Food and Drug Administration. Complex innovative trial design meeting program. <https://www.fda.gov/drugs/development‐resources/complex‐innovative‐trial‐design‐meeting‐program> (8 January 2024).
EU‐PEARL. EU‐PEARL: major depressive disorder (MDD). <https://eu‐pearl.eu/case‐studies/mdd> (15 August 2023).
EU‐PEARL. EU‐PEARL: D4.3 interim report on TRD/PRD master protocol and regulatory requirements. <https://eu‐pearl.eu/wp‐content/uploads/2023/03/EU‐PEARL_D4.3‐Interim‐Report‐on‐TRD‐PRD‐master‐protocol.pdf> (15 August 2023).
EU‐PEARL. EU‐PEARL: D4.7 TRD/PRD final report on regulatory and ethics consultation. <https://eu‐pearl.eu/wp‐content/uploads/2023/04/D4.7‐TRD‐PRD‐final‐report‐on‐Regulatory‐and‐Ethics‐Consultation.pdf> (15 June 2023).
Freitag, M.M. et al. Design considerations for a phase II platform trial in major depressive disorder. < https://arxiv.org/abs/2310.02080> (2023).
EU‐PEARL. EU‐PEARL: D6.5 NASH final report on regulatory and ethics consultation. <https://eu‐pearl.eu/wp‐content/uploads/2023/04/D6.5‐NASH‐Final‐Report‐on‐Regulatory‐and‐Ethics‐Consultation.pdf> (15 June 2023).
Meyer, E.L. et al. Designing an exploratory phase 2b platform trial in NASH with correlated, co‐primary binary endpoints. PLoS One 18, e0281674 (2023). https://doi.org/10.1371/journal.pone.0281674
EuroScan. Glossary for early awareness and HTA ‐ technology. <https://glossary.i‐hts.org/index.php?title=Technology> (16 January 2024).
European Network for Health Technology Assessment (EUnetHTA). EUnetHTA JA2 WP8 Deliverable: HTA Core Model Verison 3.0. <https://www.eunethta.eu/wp‐content/uploads/2018/03/HTACoreModel3.0‐1.pdf> (28 August 2023).
European Network for Health Technology Assessment (EUnetHTA). D4.6 validity of clinical studies. <https://www.eunethta.eu/wp‐content/uploads/2022/12/EUnetHTA‐21‐D4.6‐Practical‐Guideline‐on‐validity‐of‐clinical‐studies‐v1.0‐1.pdf> (2022).
European Medicines Agency. Draft guideline on multiplicity issues in clinical trials. EMA/CHMP /44762/2017. <https://www.ema.europa.eu/en/documents/scientific‐guideline/draft‐guideline‐multiplicity‐issues‐clinical‐trials_en.pdf> (17 January 2023).
European Medicines Agency. Reflection Paper on methodological issues in confirmatory clinical Trials planned with an Adaptive Design. CHMP/EWP/2459/02. <https://www.ema.europa.eu/en/documents/scientific‐guideline/reflection‐paper‐methodological‐issues‐confirmatory‐clinical‐trials‐planned‐adaptive‐design_en.pdf> (17 January 2023).
US Food and Drug Administration. Multiple endpoints in clinical trials: guidance for industry. <https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/multiple‐endpoints‐clinical‐trials‐guidance‐industry> (15 August 2023).
US Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics: guidance for industry. <https://www.fda.gov/media/78495/download> (17 January 2023).
Bai, X., Deng, Q. & Liu, D. Multiplicity issues for platform trials with a shared control arm. J. Biopharm. Stat. 30, 1077–1090 (2020). https://doi.org/10.1080/10543406.2020.1821703
Collignon, O. et al. Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella, and platform trials. Clin. Pharmacol. Ther. 107, 1059–1067 (2020). https://doi.org/10.1002/cpt.1804
Nguyen, Q., Hees, K. & Hofner, B. Adaptive platform trials: the impact of common controls on type one error and power. J. Biopharm. Stat., 1–18 (2023). https://doi.org/10.1080/10543406.2023.2275765
Meyer, E.L. et al. Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials. Pharm. Stat. 21, 671–690 (2022). https://doi.org/10.1002/pst.2194
Stallard, N., Todd, S., Parashar, D., Kimani, P.K. & Renfro, L.A. On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Ann. Oncol. 30, 506–509 (2019). https://doi.org/10.1093/annonc/mdz038
Parker, R.A. & Weir, C.J. Non‐adjustment for multiple testing in multi‐arm trials of distinct treatments: rationale and justification. Clin. Trials 17, 562–566 (2020). https://doi.org/10.1177/1740774520941419
Bretz, F. & König, F. Commentary on Parker and Weir. Clin. Trials 17, 567–569 (2020). https://doi.org/10.1177/1740774520941420
Robertson, D.S., Wason, J.M.S., Koenig, F., Posch, M. & Jaki, T. Online error control for platform trials. Stat. Med. 42, 2475–2495 (2023). https://doi.org/10.1002/sim.9733
Zehetmayer, S., Posch, M. & Koenig, F. Online control of the false discovery rate in group‐sequential platform trials. Stat. Methods Med. Res. 31, 2470–2485 (2022). https://doi.org/10.1177/09622802221129051
Fisher, L., Bofill Roig, M. & Brannath, W. The online closure principle (2022). <https://arxiv.org/abs/2211.11400>
Wang, R. & Ramdas, A. False discovery rate control with E‐values. J. R. Stat. Soc. Ser. B Stat Methodol. 84, 822–852 (2022). https://doi.org/10.1111/rssb.12489
Meyer, E.L. et al. The evolution of master protocol clinical trial designs: a systematic literature review. Clin. Ther. 42, 1330–1360 (2020). https://doi.org/10.1016/j.clinthera.2020.05.010
Saville, B.R., Berry, D.A., Berry, N.S., Viele, K. & Berry, S.M. The Bayesian time machine: accounting for temporal drift in multi‐arm platform trials. Clin. Trials 19, 490–501 (2022). https://doi.org/10.1177/17407745221112013
Bofill Roig, M. et al. On model‐based time trend adjustments in platform trials with non‐concurrent controls. BMC Med. Res. Methodol. 22, 228 (2022). https://doi.org/10.1186/s12874‐022‐01683‐w
Bofill Roig, M. et al. On the use of non‐concurrent controls in platform trials: a scoping review. Trials 24, 408 (2023). https://doi.org/10.1186/s13063‐023‐07398‐7
Dunnett, C.W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096–1121 (1955). https://doi.org/10.1080/01621459.1955.10501294
Dodd, L.E., Freidlin, B. & Korn, E.L. Platform trials ‐ beware the noncomparable control group. N. Engl. J. Med. 384, 1572–1573 (2021). https://doi.org/10.1056/NEJMc2102446
Bofill Roig, M., Glimm, E., Mielke, T. & Posch, M. Optimal allocation strategies in platform trials (2023). <https://arxiv.org/abs/2304.03035>
European Medicines Agency. Guideline on adjustment for baseline covariates in clinical trials. EMA/295050/2013. <https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐adjustment‐baseline‐covariates‐clinical‐trials_en.pdf> (17 January 2023).
Grieve, A.P. & Krams, M. ASTIN: a Bayesian adaptive dose‐response trial in acute stroke. Clin. Trials 2, 340–351 (2005). https://doi.org/10.1191/1740774505cn094oa
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D. & Esserman, L. I‐SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97–100 (2009). https://doi.org/10.1038/clpt.2009.68
Alexander, B.M. et al. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin. Cancer Res. 24, 737–743 (2018). https://doi.org/10.1158/1078‐0432.CCR‐17‐0764
Alexander, B.M. et al. Individualized screening trial of innovative glioblastoma therapy (INSIGhT): a Bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma. JCO Precis. Oncol. 3, 1–13 (2019). https://doi.org/10.1200/PO.18.00071
Bongard, E. et al. Antivirals for influenza‐like illness? A randomised controlled trial of clinical and cost effectiveness in primary CarE (ALIC4 E): the ALIC4 E protocol. BMJ Open 8, e021032 (2018). https://doi.org/10.1136/bmjopen‐2017‐021032
Meyer, E.L., Kumaus, C., Majka, M. & Koenig, F. An interactive R‐shiny app for quickly visualizing a tidy, long dataset with multiple dimensions with an application in clinical trial simulations for platform trials. SoftwareX 22, 101347 (2023). https://doi.org/10.1016/j.softx.2023.101347
Meyer, E.L., Mielke, T., Parke, T., Jacko, P. & König, F. SIMPLE—A modular tool for simulating complex platform trials. Software X 23, 101515 (2023). https://doi.org/10.1016/j.softx.2023.101515
Saesen, R. et al. Involvement of the European medicines agency in multi‐stakeholder regulatory science research projects: experiences of staff members and project coordinators. Front. Med. 10, 1181702 (2023). https://doi.org/10.3389/fmed.2023.1181702
European Medicines Agency. ACT EU multi‐stakeholder workshop on methodology guidance: a patient centered approach to methodologies. <https://www.ema.europa.eu/en/events/act‐eu‐pa08‐multi‐stakeholder‐methodology‐workshop#ema‐inpage‐item‐23401> (8 January 2024).
European Medicines Agency. ACT EU Multi‐stakeholder workshop: a patient‐centered approach to methodologies. Report of the methodology guidance workshop. <https://accelerating‐clinical‐trials.europa.eu/document/download/451d68ff‐a998‐43cf‐a590‐45b781c28ff1_en?filename=ACT%20EU%20multi‐stakeholder%20workshop%20on%20methodology%20guidance%20%E2%80%93%20report.pdf> (2023).
European Medicines Agency. Scientific advice working party. <https://www.ema.europa.eu/en/scientific‐advice‐working‐party> (8 January 2024).
European Medicines Agency. Methodology working party. <https://www.ema.europa.eu/en/committees/working‐parties‐other‐groups/chmp/methodology‐working‐party> (8 January 2024).